Ocular Drug Delivery Market By Technology (Topical, Ocular Insert, Intraocular Implants, In-Situ Gel, Others), By Formulation Type (Solution, Emulsion, Suspension, Ointment, Others), By Disease Indication (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome,

Ocular Drug Delivery Market By Technology (Topical, Ocular Insert, Intraocular Implants, In-Situ Gel, Others), By Formulation Type (Solution, Emulsion, Suspension, Ointment, Others), By Disease Indication (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Age related macular degeneration, Others), By End User (Hospitals, Ophthalmic Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


The ocular drug delivery market was valued for $67.7 billion in 2022 and is estimated to reach $115.5 billion by 2032, exhibiting a CAGR of 5.5% from 2023 to 2032. The targeted delivery of pharmaceuticals and therapeutic agents to the eye is known as ocular drug delivery. This delivery system aims to treat different eye diseases and ailments by efficiently and effectively delivering medications to the targeted areas of the eye, such as the cornea, conjunctiva, or retina. This drug delivery system is essential to effectively treat illnesses like glaucoma, age-related macular degeneration, dry eye disease, and others. A variety of techniques are used in ocular drug delivery, such as eye drops, ointments, implants, inserts, and cutting-edge technologies including intravitreal injections and in-situ gels.

The ocular drug delivery market growth is driven by increase in the incidences of ocular diseases, rise in aging population, and surge in development of new technologies for ocular drug delivery. Surge in aging population and shift in lifestyles are the major risk factors that contribute to the increased prevalence of eye disorders such as glaucoma, age-related macular degeneration (AMD), and others. The risk of getting age-related macular degeneration rises with the aging population. For instance, according to National Center for Biotechnology Information (NCBI) 2022, about 200 million people are estimated to have AMD and by 2040, this number is expected to reach 300 million. Thus, there is an increase in need for efficient drug delivery systems that can offer consistent and focused delivery of drugs to treat these illnesses.

Furthermore, continuous technical advancements to improve ocular drug delivery strategies are also driving the market growth. These developments are intended to enhance the effectiveness, accuracy, and patient experience while administering drugs to the eyes. For instance, sustained-release intraocular implants, such as the ILUVIEN, which deliver fluocinolone acetonide and dexamethasone, respectively, have become recognized as ground-breaking technologies. These implants ensure stable drug levels in the eye and minimize the need for frequent eye drops by releasing medication gradually over an extended period of time.

In addition, increase in R&D activities and reduced side effects of drugs due to use of advanced drug delivery technologies boost the market growth. However, stringent regulatory guidelines for the drug approvals limit the growth of the ocular drug delivery market. Furthermore, high cost associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new ocular drug delivery formulation thereby impacting the market growth. Further, shift of patient preference towards the non-invasive treatments due to ease of administration and improved compliance also drives the demand for eye drops, eye ointments, and other formulations. For instance, according to National Centers for Biotechnology Information (NCBI), topical eye drop is the most convenient and highly preferred route of drug administration.

The ocular drug delivery market is segmented on the basis of technology, formulation type, disease indication, end user, and region. On the basis of technology, the market is classified into topical, ocular insert, intraocular implants, in-situ gels, and others. As per formulation type, the market is categorized into solution, emulsion, suspension, ointment, and others. On the basis of disease indication, the market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, age related macular degeneration, and others. On the basis of end use the market is divided into hospitals, ophthalmic clinics, and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global ocular drug delivery market are Ocular Therapeutix, Inc., EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Santen Pharmaceutical Co., Ltd., Abbvie Inc., Novaliq GmbH, Bausch & Lomb, Alimera Sciences, Inc., Nicox, and Kiora Pharmaceuticals, Inc. Key players operating in the market have adopted product approval and collaboration as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ocular drug delivery market analysis from 2022 to 2032 to identify the prevailing ocular drug delivery market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the ocular drug delivery market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global ocular drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technology

Topical
Ocular Insert
Intraocular Implants
In-Situ Gel
Others

By Formulation Type

Ointment
Others
Solution
Emulsion
Suspension

By End User

Others
Hospitals
Ophthalmic Clinics

By Disease Indication

Glaucoma
Diabetic Retinopathy
Dry Eye Syndrome
Age related macular degeneration
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Bausch Health Companies, Inc.
Ocular Therapeutix, Inc.
Clearside Biomedical, Inc.
Alimera Sciences, Inc.
EyePoint Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc.
Nocox
Santen Pharmaceutical Co., Ltd.
Novaliq GmbH
AbbVie Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Technological advancements in the ocular drug delivery
3.4.1.2. Surge in prevalence of eye disorders
3.4.1.3. Rise in geriatric population
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements for product approvals
3.4.3. Opportunities
3.4.3.1. Surge in new product approvals and strong product pipeline
CHAPTER 4: OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY
4.1. Overview
4.1.1. Market size and forecast
4.2. Topical
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Ocular Insert
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Intraocular Implants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. In-Situ Gel
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Solution
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Emulsion
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Suspension
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Ointment
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Glaucoma
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diabetic Retinopathy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Dry Eye Syndrome
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Age related macular degeneration
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: OCULAR DRUG DELIVERY MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospitals
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Ophthalmic Clinics
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: OCULAR DRUG DELIVERY MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Technology
8.2.3. Market size and forecast, by Formulation Type
8.2.4. Market size and forecast, by Disease Indication
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Technology
8.2.6.1.2. Market size and forecast, by Formulation Type
8.2.6.1.3. Market size and forecast, by Disease Indication
8.2.6.1.4. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Technology
8.2.6.2.2. Market size and forecast, by Formulation Type
8.2.6.2.3. Market size and forecast, by Disease Indication
8.2.6.2.4. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Technology
8.2.6.3.2. Market size and forecast, by Formulation Type
8.2.6.3.3. Market size and forecast, by Disease Indication
8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Technology
8.3.3. Market size and forecast, by Formulation Type
8.3.4. Market size and forecast, by Disease Indication
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Technology
8.3.6.1.2. Market size and forecast, by Formulation Type
8.3.6.1.3. Market size and forecast, by Disease Indication
8.3.6.1.4. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Technology
8.3.6.2.2. Market size and forecast, by Formulation Type
8.3.6.2.3. Market size and forecast, by Disease Indication
8.3.6.2.4. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Technology
8.3.6.3.2. Market size and forecast, by Formulation Type
8.3.6.3.3. Market size and forecast, by Disease Indication
8.3.6.3.4. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Technology
8.3.6.4.2. Market size and forecast, by Formulation Type
8.3.6.4.3. Market size and forecast, by Disease Indication
8.3.6.4.4. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Technology
8.3.6.5.2. Market size and forecast, by Formulation Type
8.3.6.5.3. Market size and forecast, by Disease Indication
8.3.6.5.4. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Technology
8.3.6.6.2. Market size and forecast, by Formulation Type
8.3.6.6.3. Market size and forecast, by Disease Indication
8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Technology
8.4.3. Market size and forecast, by Formulation Type
8.4.4. Market size and forecast, by Disease Indication
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Technology
8.4.6.1.2. Market size and forecast, by Formulation Type
8.4.6.1.3. Market size and forecast, by Disease Indication
8.4.6.1.4. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Technology
8.4.6.2.2. Market size and forecast, by Formulation Type
8.4.6.2.3. Market size and forecast, by Disease Indication
8.4.6.2.4. Market size and forecast, by End User
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Technology
8.4.6.3.2. Market size and forecast, by Formulation Type
8.4.6.3.3. Market size and forecast, by Disease Indication
8.4.6.3.4. Market size and forecast, by End User
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Technology
8.4.6.4.2. Market size and forecast, by Formulation Type
8.4.6.4.3. Market size and forecast, by Disease Indication
8.4.6.4.4. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Technology
8.4.6.5.2. Market size and forecast, by Formulation Type
8.4.6.5.3. Market size and forecast, by Disease Indication
8.4.6.5.4. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Technology
8.4.6.6.2. Market size and forecast, by Formulation Type
8.4.6.6.3. Market size and forecast, by Disease Indication
8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Technology
8.5.3. Market size and forecast, by Formulation Type
8.5.4. Market size and forecast, by Disease Indication
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Technology
8.5.6.1.2. Market size and forecast, by Formulation Type
8.5.6.1.3. Market size and forecast, by Disease Indication
8.5.6.1.4. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Technology
8.5.6.2.2. Market size and forecast, by Formulation Type
8.5.6.2.3. Market size and forecast, by Disease Indication
8.5.6.2.4. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Technology
8.5.6.3.2. Market size and forecast, by Formulation Type
8.5.6.3.3. Market size and forecast, by Disease Indication
8.5.6.3.4. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Technology
8.5.6.4.2. Market size and forecast, by Formulation Type
8.5.6.4.3. Market size and forecast, by Disease Indication
8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. AbbVie Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Bausch Health Companies, Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Ocular Therapeutix, Inc.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. EyePoint Pharmaceuticals, Inc.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Clearside Biomedical, Inc.
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Key strategic moves and developments
10.6. Santen Pharmaceutical Co., Ltd.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Novaliq GmbH
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Alimera Sciences, Inc.
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. Nocox
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. Kiora Pharmaceuticals, Inc.
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
LIST OF TABLES
TABLE 01. GLOBAL OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 02. OCULAR DRUG DELIVERY MARKET FOR TOPICAL, BY REGION, 2022-2032 ($MILLION)
TABLE 03. OCULAR DRUG DELIVERY MARKET FOR OCULAR INSERT, BY REGION, 2022-2032 ($MILLION)
TABLE 04. OCULAR DRUG DELIVERY MARKET FOR INTRAOCULAR IMPLANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. OCULAR DRUG DELIVERY MARKET FOR IN-SITU GEL, BY REGION, 2022-2032 ($MILLION)
TABLE 06. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 08. OCULAR DRUG DELIVERY MARKET FOR SOLUTION, BY REGION, 2022-2032 ($MILLION)
TABLE 09. OCULAR DRUG DELIVERY MARKET FOR EMULSION, BY REGION, 2022-2032 ($MILLION)
TABLE 10. OCULAR DRUG DELIVERY MARKET FOR SUSPENSION, BY REGION, 2022-2032 ($MILLION)
TABLE 11. OCULAR DRUG DELIVERY MARKET FOR OINTMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 12. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 14. OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 15. OCULAR DRUG DELIVERY MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2022-2032 ($MILLION)
TABLE 16. OCULAR DRUG DELIVERY MARKET FOR DRY EYE SYNDROME, BY REGION, 2022-2032 ($MILLION)
TABLE 17. OCULAR DRUG DELIVERY MARKET FOR AGE RELATED MACULAR DEGENERATION, BY REGION, 2022-2032 ($MILLION)
TABLE 18. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. GLOBAL OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. OCULAR DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. OCULAR DRUG DELIVERY MARKET FOR OPHTHALMIC CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 22. OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 23. OCULAR DRUG DELIVERY MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 29. U.S. OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 30. U.S. OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 31. U.S. OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 32. U.S. OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. CANADA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 34. CANADA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 35. CANADA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 36. CANADA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. MEXICO OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 38. MEXICO OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 39. MEXICO OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 40. MEXICO OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 41. EUROPE OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 42. EUROPE OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 43. EUROPE OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 44. EUROPE OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. EUROPE OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 46. GERMANY OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 47. GERMANY OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 48. GERMANY OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 49. GERMANY OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. FRANCE OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 51. FRANCE OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 52. FRANCE OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 53. FRANCE OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. UK OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 55. UK OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 56. UK OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 57. UK OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. ITALY OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 59. ITALY OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 60. ITALY OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 61. ITALY OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. SPAIN OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 63. SPAIN OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 64. SPAIN OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 65. SPAIN OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 68. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 69. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. JAPAN OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 76. JAPAN OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 77. JAPAN OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 78. JAPAN OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. CHINA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 80. CHINA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 81. CHINA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 82. CHINA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. INDIA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 84. INDIA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 85. INDIA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 86. INDIA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 87. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 88. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 89. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 91. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 92. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 93. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 94. SOUTH KOREA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 99. LAMEA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 100. LAMEA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 101. LAMEA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 102. LAMEA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. LAMEA OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 104. BRAZIL OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 105. BRAZIL OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 106. BRAZIL OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 107. BRAZIL OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 110. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 111. SAUDI ARABIA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 114. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 115. SOUTH AFRICA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 118. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 119. REST OF LAMEA OCULAR DRUG DELIVERY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 120. ABBVIE INC.: KEY EXECUTIVES
TABLE 121. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 122. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 123. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 124. ABBVIE INC.: KEY STRATERGIES
TABLE 125. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
TABLE 126. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
TABLE 127. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
TABLE 128. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
TABLE 129. OCULAR THERAPEUTIX, INC.: KEY EXECUTIVES
TABLE 130. OCULAR THERAPEUTIX, INC.: COMPANY SNAPSHOT
TABLE 131. OCULAR THERAPEUTIX, INC.: PRODUCT SEGMENTS
TABLE 132. OCULAR THERAPEUTIX, INC.: PRODUCT PORTFOLIO
TABLE 133. EYEPOINT PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 134. EYEPOINT PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 135. EYEPOINT PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 136. EYEPOINT PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 137. CLEARSIDE BIOMEDICAL, INC.: KEY EXECUTIVES
TABLE 138. CLEARSIDE BIOMEDICAL, INC.: COMPANY SNAPSHOT
TABLE 139. CLEARSIDE BIOMEDICAL, INC.: PRODUCT SEGMENTS
TABLE 140. CLEARSIDE BIOMEDICAL, INC.: SERVICE SEGMENTS
TABLE 141. CLEARSIDE BIOMEDICAL, INC.: PRODUCT PORTFOLIO
TABLE 142. CLEARSIDE BIOMEDICAL, INC.: KEY STRATERGIES
TABLE 143. SANTEN PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 144. SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 145. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 146. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 147. NOVALIQ GMBH: KEY EXECUTIVES
TABLE 148. NOVALIQ GMBH: COMPANY SNAPSHOT
TABLE 149. NOVALIQ GMBH: PRODUCT SEGMENTS
TABLE 150. NOVALIQ GMBH: PRODUCT PORTFOLIO
TABLE 151. ALIMERA SCIENCES, INC.: KEY EXECUTIVES
TABLE 152. ALIMERA SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 153. ALIMERA SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 154. ALIMERA SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 155. NOCOX: KEY EXECUTIVES
TABLE 156. NOCOX: COMPANY SNAPSHOT
TABLE 157. NOCOX: PRODUCT SEGMENTS
TABLE 158. NOCOX: PRODUCT PORTFOLIO
TABLE 159. KIORA PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 160. KIORA PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 161. KIORA PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 162. KIORA PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. OCULAR DRUG DELIVERY MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF OCULAR DRUG DELIVERY MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN OCULAR DRUG DELIVERY MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN OCULAR DRUG DELIVERY MARKET (2023-2032)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL OCULAR DRUG DELIVERY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR TOPICAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OCULAR INSERT, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR INTRAOCULAR IMPLANTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR IN-SITU GEL, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR SOLUTION, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR EMULSION, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR SUSPENSION, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OINTMENT, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. OCULAR DRUG DELIVERY MARKET, BY DISEASE INDICATION, 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR GLAUCOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR DRY EYE SYNDROME, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR AGE RELATED MACULAR DEGENERATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. OCULAR DRUG DELIVERY MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OPHTHALMIC CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 32. COMPARATIVE SHARE ANALYSIS OF OCULAR DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 33. OCULAR DRUG DELIVERY MARKET BY REGION, 2022 AND 2032(%)
FIGURE 34. U.S. OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 35. CANADA OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 36. MEXICO OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 37. GERMANY OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 38. FRANCE OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 39. UK OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 40. ITALY OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 41. SPAIN OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF EUROPE OCULAR DRUG DELIVERY MARKET, 2022-2032 ($MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings